LBRX vs RTX · $803.4M cap vs P/E 36, rev $46.78B
LB Pharmaceuticals Inc Common Stock (LBRX) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
LB Pharmaceuticals Inc Common Stock (LBRX) is a biotechnology company listed on NASDAQ.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
LBRX does not have a complete income-statement cache yet.
Latest reported RTX revenue for 2026-06-30 was $46.78B. Net income was $4.20B. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
LBRX currently screens at market cap $803.4M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the LBRX and RTX stock pages for the full models.
Not investment advice.